Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600131690) titled 'A Study of Sonrotoclax Combined With Glofitamab and GemOx for Relapsed or Refractory Large B-Cell Lymphoma' on Sept. 5.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: The First Affiliated Hospital of Soochow University
Condition:
CD20-positive relapsed or refractory large B-cell lymphoma, including DLBCL-NOS, transformed large B-cell lymphoma, EBV-positive large B-cell lymphoma, high-grade B-cell lymphoma, and double-hit/triple-hit lymphoma.
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-09-30
Target Sample Size: Sonrotoclax + Glofitamab + GemOx...